|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/14/22 Black Bird Biotech, Inc. 10-Q 9/30/22 75:46M Discount Edgar/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 841K
2: EX-10.1 Securities Purchase Agreement HTML 27K
3: EX-10.2 Security Agreement HTML 27K
4: EX-10.3 Securities Purchase Agreement HTML 22K
5: EX-10.4 Senior Secured Promissory Note HTML 25K
6: EX-10.5 Convertible Promissory Note HTML 22K
7: EX-10.6 Warrant HTML 22K
8: EX-10.7 Warrant HTML 22K
9: EX-31.1 Certification -- §302 - SOA'02 HTML 24K
10: EX-31.1 Certification -- §302 - SOA'02 HTML 25K
11: EX-32.1 Certification -- §906 - SOA'02 HTML 21K
17: R1 Cover HTML 71K
18: R2 Consolidated Balance Sheets HTML 112K
19: R3 Consolidated Balance Sheets (Parenthetical) HTML 43K
20: R4 Consolidated Statements of Operations (Unaudited) HTML 117K
21: R5 Consolidated Statement of Changes in Stockholders' HTML 107K
Equity (Deficit) (Unaudited)
22: R6 Consolidated Statements of Cash Flows (Unaudited) HTML 104K
23: R7 Basis of Presentation and Nature of Operations HTML 26K
24: R8 Summary of Significant Accounting Policies and HTML 34K
Going Concern
25: R9 Coronavirus Pandemic HTML 22K
26: R10 Concentration of Credit Risk HTML 22K
27: R11 Convertible Promissory Notes Third Parties HTML 65K
28: R12 Common Stock HTML 49K
29: R13 Preferred Stock HTML 22K
30: R14 Warrants HTML 25K
31: R15 Securitis Exchange Agreements HTML 30K
32: R16 Related Party Transactions HTML 36K
33: R17 Loans Payable Related Parties HTML 27K
34: R18 Amendments of Articles of Incorporation HTML 31K
35: R19 New Mitexstream Agreement HTML 28K
36: R20 Asset Purchase Agreement HTML 23K
37: R21 Intangible Asset HTML 22K
38: R22 Stockholder Receivable HTML 22K
39: R23 Subsequent Events HTML 24K
40: R24 Summary of Significant Accounting Policies and HTML 50K
Going Concern (Policies)
41: R25 Convertible Promissory Notes Third Parties HTML 41K
(Tables)
42: R26 Common Stock (Tables) HTML 34K
43: R27 Securities Exchange Agreements (Tables) HTML 28K
44: R28 Related Party Transactions (Tables) HTML 26K
45: R29 New Mitexstream Agreement (Tables) HTML 26K
46: R30 Summary of Significant Accounting Policies and HTML 29K
Going Concern (Details Narrative)
47: R31 Concentration of Credit Risk (Details Narrative) HTML 22K
48: R32 Convertible Promissory Notes Third Parties HTML 31K
(Details)
49: R33 Convertible Promissory Notes Third Parties HTML 37K
(Details 1)
50: R34 Convertible Promissory Notes Third Parties HTML 43K
(Details 2)
51: R35 Convertible Promissory Notes Third Parties HTML 27K
(Details 333)
52: R36 Convertible Promissory Notes Third Parties HTML 211K
(Details Narrative)
53: R37 Common Stock (Details) HTML 29K
54: R38 Common Stock (Details 1) HTML 29K
55: R39 Common Stock (Details 2) HTML 29K
56: R40 Common Stock (Details Narrative) HTML 91K
57: R41 Preferred Stock (Details Narrative) HTML 24K
58: R42 Warrants (Details Narrative) HTML 53K
59: R43 Securities Exchange Agreements (Details ) HTML 34K
60: R44 Securities Exchange Agreements (Details Narrative) HTML 36K
61: R45 Related Party Transactions (Details) HTML 36K
62: R46 Related Party Transactions (Details Narrative) HTML 82K
63: R47 Loans Payable Related Parties (Details Narrative) HTML 37K
64: R48 Amendment of Articles of Incorporation (Details HTML 29K
Narrative)
65: R49 New Mitexstream Agreement (Details) HTML 34K
66: R50 Asset Purchase Agreement (Details Narrative) HTML 34K
67: R51 Intangible Asset (Details Narrative) HTML 23K
68: R52 Stockholder Receivable (Details Narrative) HTML 22K
69: R53 Subsequent Events (Details Narrative) HTML 35K
70: R54 Convertible Promissory Notes Third Parties HTML 37K
(Details 3)
73: XML IDEA XML File -- Filing Summary XML 124K
71: XML XBRL Instance -- bbbt_10q_htm XML 993K
72: EXCEL IDEA Workbook of Financial Reports XLSX 116K
14: EX-101.CAL XBRL Calculations -- bbbt-20220930_cal XML 133K
16: EX-101.DEF XBRL Definitions -- bbbt-20220930_def XML 531K
13: EX-101.LAB XBRL Labels -- bbbt-20220930_lab XML 809K
15: EX-101.PRE XBRL Presentations -- bbbt-20220930_pre XML 716K
12: EX-101.SCH XBRL Schema -- bbbt-20220930 XSD 193K
74: JSON XBRL Instance as JSON Data -- MetaLinks 294± 393K
75: ZIP XBRL Zipped Folder -- 0001477932-22-008521-xbrl Zip 181K
EXHIBIT 31.2
CERTIFICATION
I, William E. Sluss, certify that:
| 1. | I have reviewed this Quarterly Report on Form 10-Q of Back Bird Biotech, Inc. for the fiscal period ended September 30, 2022. |
|
|
|
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
|
|
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report; |
|
|
|
| 4. | The Registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have: |
|
| (a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
|
|
|
|
| (b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
|
|
|
|
| (c) | Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
|
|
|
|
| (d) | Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and |
| 5. | The Registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions): |
|
| (a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize, and report financial information; and |
|
|
|
|
|
| (b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting. |
| Date: November 14, 2022. |
| |
|
|
|
|
| By: | /s/ William E. Sluss |
|
|
| Chief Financial Officer |
|
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 11/14/22 | None on these Dates | ||
| For Period end: | 9/30/22 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/24/23 Black Bird Biotech, Inc. S-1/A 90:6.3M Discount Edgar/FA 2/07/23 Black Bird Biotech, Inc. S-1 94:10M Discount Edgar/FA |